Absorption and Metabolism of cis-9,trans-11-CLA and of Its Oxidation Product 9,11-Furan Fatty Acid by Caco-2 Cells by Buhrke, Thorsten et al.
ORIGINAL ARTICLE
Absorption and Metabolism of cis-9,trans-11-CLA and of Its
Oxidation Product 9,11-Furan Fatty Acid by Caco-2 Cells
Thorsten Buhrke • Roswitha Merkel •
Imme Lengler • Alfonso Lampen
Received: 15 August 2011/Accepted: 22 December 2011/Published online: 18 January 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract Furan fatty acids (furan-FA) can be formed by
auto-oxidation of conjugated linoleic acids (CLA) and may
therefore be ingested when CLA-containing foodstuff is
consumed. Due to the presence of a furan ring structure,
furan-FA may have toxic properties, however, these sub-
stances are toxicologically not well characterized so far.
Here we show that 9,11-furan-FA, the oxidation product of
the major CLA isomer cis-9,trans-11-CLA (c9,t11-CLA),
is not toxic to human intestinal Caco-2 cells up to a level of
100 lM. Oil-Red-O staining indicated that 9,11-furan-FA
as well as c9,t11-CLA and linoleic acid are taken up by the
cells and stored in the form of triglycerides in lipid drop-
lets. Chemical analysis of total cellular lipids revealed that
9,11-furan-FA is partially elongated probably by the
enzymatic activity of cellular fatty acid elongases whereas
c9,t11-CLA is partially converted to other isomers such as
c9,c11-CLA or t9,t11-CLA. In the case of 9,11-furan-FA,
there is no indication for any modiﬁcation or activation of
the furan ring system. From these results, we conclude that
9,11-furan-FA has no properties of toxicological relevance
at least for Caco-2 cells which serve as a model for
enterocytes of the human small intestine.
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Abbreviations
BSA Bovine serum albumin
CLA Conjugated linoleic acid
DMEM Dulbecco’s modiﬁed Eagle’s medium
DMSO Dimethylsulfoxide
FCS Fetal calf serum
Furan-FA Furan fatty acid
GC/MS Gas chromatography/mass spectrometry
LNA Linoleic acid
Introduction
Conjugated linoleic acids (CLA) are polyunsaturated fatty
acids that are present in many natural food sources. The
term CLA describes a group of positional and geometric
isomers of linoleic acid (LNA) derivatives having conju-
gated double bounds. The conversion from LNA to CLA
occurs in the rumen of ruminants by bacterial metabolic
activity [1]. Therefore, the main source for CLA taken up
by humans is foodstuff derived from ruminants such as
milk or meat.
Over the last decade the interest in CLA has arisen
because various publications suggested that CLA may have
many different positive physiological effects. In vitro, CLA
inhibited the growth of various human cancer cells such as
colon [2], mammary [3] and prostate [4] cancer cell lines.
This anticarcinogenic effect was also determined in vivo
where supplementation with CLA resulted in a decreased
size of chemically or genetically induced tumors in
experimental animals (reviewed in [5]). In addition, CLA
seem to prevent atherosclerosis [6, 7, 8] and may improve
the immune system [9, 10]. On the other hand, some
publications describe negative effects of CLA supplemen-
tation, i.e. the induction of non-alcoholic hepatic steatosis
in mice [11], the decrease of insulin sensitivity in human
subgroups [12], or the increase in proinﬂammatory cyto-
kines in human adipocytes in vitro [13]. In the past decade,
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DOI 10.1007/s11745-012-3653-6attention has predominantly been drawn on a potential anti-
adipogenic role of CLA as these substances are proposed to
have a positive effect on body composition by decreasing
body fat mass and increasing lean muscle mass (reviewed
in [14]). In the case of body composition, the CLA isomer
trans-10, cis-12-CLA (t10,c12-CLA) seems to be respon-
sible for reduction of body fat [15]. On the other hand, it
was proposed that the isomer cis-9,trans-11-CLA (c9,t11-
CLA) was more effective concerning the inhibition of
tumor development [16]. Milk and meat of ruminant ani-
mals contain 28 different CLA isomers, and the most
abundant isomer in food is the c9,t11-CLA isomer, which
represents up to 80% of total CLA.
Due to the reported positive effects of CLA on body
mass composition and despite controversial data and some
observed negative effects of CLA, these compounds are
already available in numerous formulas of food supple-
ments and are currently being discussed for their use as
food additives. CLA are classiﬁed as ‘‘novel foods’’ in
Europe and a premarketing risk assessment of CLA is a
mandatory part of the novel food approval. For a reliable
risk assessment of CLA it is necessary to focus additionally
on the oxidation products of CLA, the furan fatty acids
(furan-FA).
Furan-FA are comprised of a furan ring ﬂanked by one
alkyl and one carboxyl side chain in the a-positions of the
furan ring. It has been shown that in the presence of air
CLA can react with dioxygen to form furan-FA [17]
(Fig. 1). Therefore, if CLA-containing food supplements
are consumed, signiﬁcant amounts of furan-FA may be
taken up by the consumer in parallel. Up to now, hardly
anything is known about the toxicological potential of
furan-FA. The presence of the aromatic furan ring system
in furan-FA gives rise to the assumption that these com-
pounds may have hazard potential since furan itself and
numerous furan derivatives have shown themselves to have
properties of toxicological relevance (reviewed in [18]).
The aim of our study was to investigate the absorption and
the metabolism of furan-FA by human intestinal cells. The
well-established Caco-2 system was employed for this
study as it is a widely used in vitro model for the intestinal
barrier. Differentiated Caco-2 cells are known to form a
tight cellular monolayer with morphological and bio-
chemical properties very similar to those of enterocytes of
the small intestine [19, 20]. In addition, the Caco-2 system
is a well-established model for intestinal lipid metabolism
[21].
Experimental Materials and Methods
Chemicals and Fatty Acids
All chemicals were purchased from Merck (Darmstadt,
Germany) or Sigma-Aldrich (Taufkirchen, Germany) in the
highest available purity. The CLA isomers cis-9,trans-11-
octadecadienoic acid (c9,t11-CLA) and the furan fatty acid
9,12-epoxy-9,11-octadecadienoic acid (9,11-furan-FA)
were obtained from Biotrend (Ko ¨ln, Germany). LNA was
purchased from Sigma-Aldrich (Taufkirchen, Germany).
All fatty acids were dissolved in DMSO to get 0.1 M stock
solutions.
Cell Culture and Treatment with Fatty Acids
Cells were obtained from the European Collection of Cell
Culture (ECACC). Culture media and supplements were
obtained from PAA Laboratories GmbH (Pasching, Aus-
tria). The human adenocarcinoma cell line Caco-2
(ECACC No. 860 10 202) was cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with
10% fetal calf serum, 100 U/ml penicillin and 100 lg/ml
streptomycin in a humidiﬁed atmosphere of 5% CO2 at
37 C. Cells were passaged every 3–4 days by treatment
with 0.1% trypsin and 0.04% EDTA and then plated at a
density of 1.3–2 9 10
4 cells/cm
2.
For experimentally treatment with fatty acids, cells were
allowed to attach by cultivating overnight in medium con-




c9,t11-CLA Fig. 1 Structures of LNA,
c9,t11-CLA and 9,11-furan-FA
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123(ITS, Invitrogen, Karlsruhe, Germany) and 0.1 mg/ml fatty
acid-freeBSA(Sigma-Aldrich,Taufkirchen,Germany)with
various concentrations of the respective fatty acid with a
molar ratio of fatty acid to BSA of 4:1.
Oil-Red-O Staining
Caco-2 cells were cultivated on cover slips in 24-well
plates with 40,000 cells/well. After 48 h of treatment with
fatty acids staining with Oil-Red-O (Sigma-Aldrich,
Taufkirchen, Germany) was performed. Cells were washed
with Phosphate Buffered Saline (PBS) and ﬁxed with 3.7%
formaldehyde for 1 h. 0.3% Oil-Red-O in isopropanol was
then added directly to the ﬁxed cells and incubated for 1 h.
The microscopy studies were performed with a Axio
Observer microscope equipped with a digital camera
(Zeiss, Jena, Germany).
Cell Viability Assay
Cells were plated in 96-well plates with 7,500 cells/well for
Caco-2 cells in 100 ll medium. After 2 days of treatment
with fatty acids cell viability was estimated by the Cell-
Titer-Blue
 Cell Viability Assay (CTB Assay) (Promega,
Madison, WI). Assays were performed by adding 20 llo fa
1:4 dilution of the CTB reagent in phosphate-buffered sal-
ine (PBS) directly to the cells cultured in 100 ll medium,
incubating for 1 h at 37 C and then measuring ﬂuorescence
at 540/590 nm with a Mithras Multimode Reader LB 940
(Berthold Technologies, Vienna, Austria). Values are
expressed as percentages of the negative control which was
exposed to medium containing 0.1% DMSO and which was
taken as 100%. As a positive control for cytotoxicity: cells
were exposed to medium containing 0.05% Triton X-100.
Extraction of Total Cellular Lipids and Fatty Acid
Derivatization
Caco-2 cells were incubated with 100 lM of LNA, c9,t11-
CLA or 9,11-furan-FA for 48 h. Cells were washed twice
with PBS, and after treatment with trypsin/EDTA cells
were transferred to reaction tubes. 20 llo fa1 0 m M
solution of butylated hydroxytoluene (BHT) in acetonitrile
was applied to the cell suspensions to protect the lipids
from oxidative damage. Subsequently, cells were lyophi-
lized to completely remove the water and total lipids were
extracted twice from the dried cell pellet with 0.7 ml of a
2:1 (v/v) chloroform:methanol mixture. 150 ll of a 20%
solution of BF3 in methanol was applied to the lipid
extracts, and transmethylation was conducted for 10 min at
70 C. Methylated fatty acids were extracted with 1 ml of
hexane, dried over anhydrous sodium sulfate, concentrated
in vacuo and ﬁnally dissolved in 200 ll hexane.
GC/MS Analysis
GC/MS analysis was conducted with an Agilent 7890A gas
chromatograph coupled to an Agilent MSD 5975C mass
spectrometer. Methylated fatty acids were separated with
an Rt-2560 column (100 m 9 0.25 mm 9 0.2 lm; Restek,
Bad Homburg, Germany) by using helium as the carrier gas
at a ﬂow rate of 1 ml/min. 2 ll of each samples was
applied to the cold injection system (splitless mode, 15 C)
by taking advantage of an MP5 autosampler (Gerstel,
Mu ¨lheim, Germany). The oven program was as follows:
6 min at 35 C, ramp to 165 Ca t6 5C/min, 2 min at
165 C, 1 min at 180 C, 0.5 min at 190 C, 1 min at
210 C. Methylated fatty acids were identiﬁed by com-
parison of retention times with authentic standards and by
the fragmentation pattern in the mass spectra. The artiﬁcial
methylated fatty acid C19:0 was used as the internal
standard. Mass spectra were recorded both in the SCAN
modus and in the SIM modus to increase sensitivity. The
quantitation limit of the method was 0.25 ng/ll for each
individual fatty acid.
Results
Viability of Caco-2 Cells
In this study we focused on c9,t11-CLA, the major
CLA isomer in foodstuff, and on its oxidation product
9,11-furan-FA. Moreover, the metabolic precursor of
c9,t11-CLA, LNA, was included in the study.
To analyse potential cytotoxic effects of LNA, c9,t11-
CLA and 9,11-furan-FA, Caco-2 cells were incubated with
various concentrations of these substances. Subsequently,
cellular viability was tested by using the CTB assay. As
shown in Fig. 2, incubation of the cells with up to 100 lM
of the respective substance did not affect cellular viability
whereas cellular viability was decreased to a level of about
3% upon incubation of the cells with medium containing
0.05% Triton X-100 which was used as positive control.
Thus, none of the substances tested in this study displayed
cytotoxic potential to Caco-2 cells up to a level of 100 lM.
Fatty Acid Absorption by Caco-2 Cells
Caco-2 cells have the capacity to absorb free fatty acids
and to incorporate them into triglycerides for storage in
lipid droplets [22]. To analyze whether the enzymatic
machinery of Caco-2 accepts furan-FA as a fatty acid-type
substrate at all, lipid droplet staining was conducted with
LNA-, CLA- and furan-FA-treated cells in order to visu-
alize cellular absorption of the respective fatty acid. Caco-2
cells were incubated either with LNA, c9,t11-CLA, or
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1239,11-furan-FA, and Oil-Red-O-staining of the cells was
conducted after 48 h of incubation in order to visualize the
formation of intracellular lipid droplets. In control cells,
intracellular red stain was rarely visible, whereas numerous
small lipid droplets were stained in cells that had been
incubated with 10 lM LNA, c9,t11-CLA or 9,11-furan-FA
(Fig. 3). Incubation of the cells with 100 lM of the
respective free fatty acid yielded cells full of large lipid
droplets (Fig. 3). Therefore, Fig. 3 clearly illustrates that
lipid droplet formation in Caco-2 cells increased with
increasing concentrations of free fatty acid offered to the
cells, independent of the type of fatty acid. Moreover,
microscopic inspection of numerous cells indicated that
Caco-2 cells treated with 100 lM of the respective fatty
acid tend to be enlarged in size due to lipid droplet for-
mation. In these experiments there was no observation of
speciﬁc alterations in cell morphology such as shrinking of
the cells that might point to toxic effects induced by fatty
acid treatment. Thus, in sum, Caco-2 cells seem to absorb
9,11-furan-FA and to store it as triglycerides in lipid
droplets as they do with LNA and c9,t11-CLA.
Analysis of Fatty Acid Composition
To follow the fate of the fatty acids taken up by the cells, a
GC/MS method was employed to analyze cellular fatty
acid composition in more detail. For this purpose, total
cellular lipids were extracted from Caco-2 cells that had
been incubated with 100 lM of LNA, c9,t11-CLA, or 9,11-
furan-FA, respectively. After lipid hydrolysis and fatty acid
derivatization, the resulting mixture of fatty acid methyl
esters was separated by gas chromatography. Fatty acid
identiﬁcation was achieved by subsequent MS analysis of
individual peaks. The relative amount of the respective
fatty acid was calculated from the peak area in relation to
the peak area of the internal standard. The results of this
analysis are summarized in Table 1.
Incubation of the cells with LNA resulted in an
approximately four-fold increase in the relative intracel-
lular content of LNA and in a concomitant relative
decrease of the amount of the other fatty acids with two
exceptions. Compared to the control cells, the relative
amount of the well-known LNA-metabolite 20:4n-6
increased upon incubation of the cells with LNA. In
addition, a small amount of t9,t11-CLA was detectable in
the samples obtained from LNA-incubated cells.
In the case of c9,t11-CLA, an approx. 20-fold increase
in the relative intracellular amount of this substance was
observed. In addition, the relative amount of the CLA
isomers c9,c11-CLA and t9,t11-CLA increased whereas
the relative content of the remaining fatty acids decreased.
Incubation of the cells with 9,11-furan-FA yielded an
approx. 20-fold increase in the relative intracellular amount
of this compound and a simultaneous decrease of the rel-
ative content of all other fatty acids. There was, however,
an additional peak in the gas chromatogram that was nei-
ther present in the chromatogram of the control cells nor in
the chromatograms of the cells incubated with LNA or
c9,t11-CLA. The peak area of the additional peak was at a
level of about 10% compared to the area of the 9,11-furan-
FA peak (data not shown). Comparison of the mass spectra
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Fig. 2 Viability of Caco-2 cells. Cells were treated with various
concentrations of (a) LNA, (b) c9,t11-CLA, and (c) 9,11-furan-FA for
48 h. Cellular viability was determined using the CTB assay and
expressed as percentages of negative control which was exposed to
medium containing 0.1% DMSO (set as 100%). Data are expressed as
the means ± SD; n = 5
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123additional peak revealed that this substance must be a
metabolite of 9,11-furan-FA (Fig. 4). Two major peaks
with m/z 165 and m/z 179 in the mass spectrum of 9,11-
furan-FA (Fig. 4a) can be explained by the cleavage of the
compound between carbon atoms C7 and C8, and between
C6 and C7, respectively. Additional b-cleavage of these
products between C13 and C14 results in masses of m/z 95
and m/z 107, respectively, additional major peaks in
spectrum of Fig. 4a. Since these four masses are also
present in the mass spectrum of the unknown metabolite
(Fig. 4b), it can be concluded that this metabolite is a
derivative of 9,11-furan-FA. Moreover, preservation of
these four masses indicates that the furan ring is still intact
in the metabolite and that it was not altered upon cellular
metabolic activity.
Since the molecule peak of 9,11-furan-FA with m/z 308
(Fig. 4a) was shifted to a mass of m/z 336 (Fig. 4b), the
mass of the metabolite has increased by 28 atomic units
(a.u.). In addition, the series of m/z 237, m/z 251, m/z 265
and m/z 277 of Fig. 4a has shifted by 28 a.u. to m/z 265,
m/z 279, m/z 293 and m/z 305, respectively, in Fig. 4b. The
increase of 28 a.u. can be explained by the addition of two
methylene groups to 9,11-furan-FA, resulting in the C20-
derivative as depicted in the insert of Fig. 4b.
Fig. 3 Oil-Red-O staining.
Caco-2 cells were incubated
with LNA, c9,t11-CLA, or 9,11-
furan-FA for 48 h. Oil-Red-O
staining was conducted as
described in the methods
section. Red staining is
indicative of lipid droplets
(color ﬁgure online)
Table 1 Incorporation of LNA,
c9,t11-CLA, and 9,11-furan-FA,
respectively, into the total
cellular lipids of Caco-2 cells
after 48 h of incubation
nd not detected
Fatty acid (wt. %) Control LNA c9,t11-CLA 9,11-furan-FA
16:0 6.10 ± 2.72 2.56 ± 1.22 0.92 ± 0.30 0.22 ± 0.06
18:0 50.87 ± 6.41 41.68 ± 4.83 30.21 ± 2.98 13.18 ± 1.61
18:1n-7 5.06 ± 0.57 4.53 ± 0.92 2.31 ± 0.81 2.61 ± 0.44
18:1n-9 5.07 ± 1.54 2.47 ± 0.93 1.98 ± 1.06 1.21 ± 0.33
20:0 4.27 ± 0.55 1.99 ± 0.75 1.31 ± 0.38 0.43 ± 0.14
20:1n-9 3.67 ± 0.46 1.18 ± 0.27 0.78 ± 0.21 0.72 ± 0.22
20:4n-6 12.10 ± 1.37 17.22 ± 3.88 4.00 ± 0.88 3.59 ± 0.52
c9,c11-CLA nd nd 2.55 ± 0.88 nd
t9,t11-CLA nd 0.58 ± 0.26 6.57 ± 1.00 0.07 ± 0.04
LNA 6.44 ± 1.13 23.32 ± 4.29 2.80 ± 0.52 1.03 ± 0.26
c9,t11-CLA 2.19 ± 0.53 1.54 ± 0.49 44.50 ± 4.27 0.20 ± 0.09
9,11-furan-FA 4.23 ± 0.93 2.93 ± 0.79 1.92 ± 0.79 76.71 ± 2.58
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123Discussion
In the past decades, CLA have been intensively investi-
gated in numerous in vivo and in vitro studies. These
substances are supposed to have various positive effects on
human health. Therefore, CLA are already available as
food supplements, and the risks and beneﬁts of supple-
mentation of foodstuff with CLA are currently under dis-
cussion. Surprisingly, the putative presence of furan-FA in
CLA preparations plays no role in these discussions so far,
although it was shown that furan-FA might arise from auto-
oxidation of CLA in the presence of molecular oxygen
[17]. From a toxicological point of view, furan-FA are of
particular interest because furan-FA harbor a furan ring
system, and furan and furan derivatives have been shown to
be toxic compounds (reviewed in [18, 23, 24]). In the liver,
furan and furan derivatives are activated by CYP2E1 to
form epoxides, and subsequently these epoxides are further
converted to yield aldehydes in some cases [25–27].
Epoxides as well as aldehydes can directly react with lip-
ids, proteins or DNA and are therefore toxic to cellular
systems. Due to their reactivity to DNA, they are potent
mutagens. Therefore, the toxicological characterization of
furan-FA has to be conducted in parallel to the current risk
and beneﬁt assessment of CLA supplementation.
It is well-known that plants produce furan-FA as sec-
ondary metabolites. These furan-FA of plant origin carry
methyl groups at one or both b-positions of the furan ring. If
these compounds are ingested with food, the methyl groups
























































































Fig. 4 Mass spectra of (a) 9,11-furan-FA and of (b) the metabolite that was formed upon incubation of Caco-2 cells with 9,11-furan-FA. The
masses of the major cleavage products are assigned to the structures of the respective molecule
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123groups and the resulting urofuran acids are then excreted via
the kidney (reviewed in [28]). In contrast to the plant furan-
FA, the furan-FA analyzed in this study is an oxidation
product of c9,t11-CLA and does not carry substituents at the
b-positions of the furan ring. There are only few examples
for non-substituted furan-FA in nature. A few non-substi-
tuted furan-FA have been isolated only from marine spon-
ges so far, and preliminary in vitro studies revealed
considerable cytotoxic potential of these isolates [29, 30].
The furan-FA analyzed in this study, however, showed no
cytotoxic effect up to a concentration of 100 lM.
The Caco-2 cell line used in this study serves as a model
for human intestinal enterocytes. Caco-2 cells have been
shown to be capable of lipid metabolism including tri-
glyceride synthesis and lipid droplet formation. Moreover,
these cells express numerous P450 enzymes and have the
capacity to detoxify various compounds. Among others, the
CYP2E1 enzyme has shown itself to be expressed by Caco-
2 cells [31]. Therefore, the Caco-2 system was the ideal
model to study uptake and metabolism of furan-FA by
human intestinal cells, because triglyceride formation as
well as b-oxidation and CYP-mediated activation of the
furan ring could be examined by using this cell line. Our
results indicate that furan-FA are taken up by the cells,
esteriﬁed to triglycerides and stored in lipid droplets. At
ﬁrst glance, there seems to be no difference in the uptake
and conversion of LNA, CLA and the corresponding furan-
FA by Caco-2 cells. Hydrolysis of total cellular lipids and
subsequent fatty acid quantiﬁcation revealed that LNA and
CLA were partly converted to related fatty acids by the
cells (Table 1).
In the case of LNA, a relative increase in arachidonic
acid (20:4n-6) was observed. It is well-known that mam-
malian cells have the capacity to use LNA as a precursor
for the formation of 20:4n-6. Fatty acid elongation is
facilitated by the activity of ELOVL5, a member of the
ELOVL (elongation of very long chain fatty acid) protein
family [32, 33] followed by the subsequent insertion of two
additional double bonds. Thus, based on our lipid analysis,
there is some indication that Caco-2 cells do not only take
up fatty acid and store them as triglycerides in lipid
droplets, but the cells also seem to elongate fatty acids
prior to triglyceride formation.
Incubation of the cells with c9,t11-CLA resulted in a
relative increase in the CLA isomers c9,c11-CLA and
t9,t11-CLA (Table 1). It has recently been shown that the
human colon cell line HT-29 can convert t11,t13-CLA into
its isomer c9,t11-CLA probably by an enzymatic two-step
saturation/desaturation reaction [34]. This might explain the
appearance of the c9,c11-CLA isomer in our experiment but
can not explain the presence of the t9,t11-CLA isomer as
mammalian cells do not introduce trans double bonds into
fatty acids. We can not exclude that cis–trans isomerization
might have occurred chemically during sample preparation
or derivatization. By using a solution of c9,t11-CLA in
control experiments, however, there was no indication of
cis–trans isomerization under the given experimental con-
ditions (data not shown). Finally, the unexpectedly high
amounts of the different CLA isomers and of 9,11-furan-FA
already in the control cells might have been due to the fact
that the cells had been incubated in a medium containing
10% fetal calf serum (FCS) that may contain signiﬁcant
amounts of bovine-speciﬁc fatty acids.
Lipid extracts from cells incubated with 9,11-furan-FA
yielded an additional peak in the gas chromatogram that
was not detected with extracts from cells that had been
treated with LNA or c9,t11-CLA. Based on the corre-
sponding mass spectrum, we propose a structure for the
furan-FA-derived metabolite as presented in Fig. 4b. From
a biological point of view, the presence of this compound
can simply be explained by the elongation of 9,11-furan-
FA probably again by the action of a member of the
ELOVL protein family and the subsequent reduction of the
condensation product as described for LNA above.
Finally, GC/MS analysis of fatty acid extracts derived
from furan-FA-treated Caco-2 cells gave no indication for
any modiﬁcation at the furan ring system. There were no
metabolites detected that might have been formed upon
epoxide formation or any other modiﬁcation of the furan
ring. Therefore, furan-FA might be either not accepted as a
substrate for the cellular CYP machinery, or esteriﬁcation
of furan-FA to form triglycerides and subsequent storage in
lipid droplets might be favoured in comparison to the
postulated oxidative conversion of the furan ring. In con-
clusion, furan-FA taken up by human intestinal cells seem
to end up preferentially in lipid metabolic pathways such as
fatty acid elongation and triglyceride formation, whereas
the furan ring present in furan-FA does not seem to be
attacked by detoxifying enzymes. In vivo, intestinal cells
pack triglycerides into chylomicrones which are VDL-like
particles and secrete them into the blood stream. These
chylomicrones are then taken up by liver cells where they
are further metabolized. Since our results indicate that the
furan ring system of furan-FA was not affected by the
metabolic activity of intestinal cells, we will address
the question in future studies as to whether the furan ring
might be attacked by liver metabolic activity.
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